Translate this page into:
Letters to Editor
doi:
10.4103/2278-330X.130480
NK cell therapy for end‑stage cancerous patient: A case study
1
New City Osaki Clinic, Tokyo, Japan
2
Vitallife Wellness Center at Bumrungrad International, BKK, Thailand
3
Hainan Medical University, China
*Corresponding author: Dr. Kamon Chaiyasit
MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Disclaimer:
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
References
- Bordignon C, Carlo-Stella C, Colombo MP, De Vincentiis A, Lanata L, Lemoli RM, et al. Cell therapy: Achievements and perspectives. Haematologica 1999;84:1110-49.
- Ames E, Murphy WJ. Advantages and clinical applications of natural killer cells in cancer immunotherapy. Cancer Immunol Immunother 2014;63:21-8.
- Campbell KS, Hasegawa J. Natural killer cell biology: An update and future directions. J Allergy Clin Immunol 2013;132:536-44.
- Ejiri Y, Ohara M, Suzuki T, Kasukawa R. Cancer cell cycle and adoptive immunotherapy using lymphokine-activated killer cells. Fukushima J Med Sci 1997;43:61-73.
- Yannelli JR. The preparation of effector cells for use in the adoptive cellular immunotherapy of human cancer. J Immunol Methods 1991;139:1-16.